Effect of immunization on herpes simplex virus type 1 latent infection in the trigeminal ganglion

References

• Nash AA. Cell-mediated immune responses in herpes simplex virus-infected mice. Prog Brain Res. 1983;59 :185–187.
   Google Scholar
• Simmons A, Tscharke D, Speck P. The role of immune mechanisms in control of herpes simplex virus infection of the peripheral nervous system. Curr Top Microbiol Immunol. 1992;179:31–56.
   Google Scholar
• Deshpande SP, Kumaraguru U, Rouse BT. Why do we lack an effective vaccine against herpes simplex virus infec-tions? Microbes Infect. 2000;2:973–978.
   Google Scholar
• Cremer KJ, Mackett M, Wohlenberg C, Notkins AL, Moss B. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science. 1985;228: 737–740.
   Google Scholar
• Bernstein DI, Stanberry LR. Herpes simplex virus vac-cines. Vaccine. 1999;17:1681–1689.
   PubMed Web of Science ®Google Scholar
• Dalai SK, Pesnicak L, Miller GF, Straus SE. Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J Neurovirol. 2002;8:35–44.
   Web of Science ®Google Scholar
• LeBlanc RA, Pesnicak L, Godleski M, Straus SE. Treat-ment of HSV-1 infection with immunoglobulin or acy-clovir: Comparison of their effects on spread, latency, and reactivation. Virology. 1999;262:230–236.
   Google Scholar
• Burke RL. Development of a herpes simplex virus subunitglycoprotein vaccine for prophylactic and therapeutic use. Reviews of Infectious Diseases. 1991;13(Suppl 11): S906–S911.
   Google Scholar
• Frye TD, Chiou HC, Hull BE, Higley NJ. The efficacy of aDNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge. Arch Virol. 2002147:1747-1759.
   Google Scholar
• Mercadal CM, Slaoui M, Brown SM, Rouse BT. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice. Viral Immunol. 1993;6:35–42.
   PubMedGoogle Scholar
• Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. Journal of Infectious Diseases. 1988;158: 602–614.
   Google Scholar
• Wachsman M, Kulka M, Smith CC, Aurelian L. A growth and latency compromised herpes simplex virus type 2 mutant (ICPODeltaPK) has prophylactic and therapeutic activity in guinea pigs. Vaccine. 200119:1879-1890.
   PubMed Web of Science ®Google Scholar
• Morrison LA, Knipe DM. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology. 1996;220:402–413.
   Google Scholar
• Morrison LA, Knipe DM. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology. 1997;239:315–326.
   PubMed Web of Science ®Google Scholar
• Walker J, Leib DA. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine. 1998;16:1–5.
   PubMed Web of Science ®Google Scholar
• Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, Minson AC. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol. 1994;68:927–932.
   PubMed Web of Science ®Google Scholar
• Irie H, Shimeld C, Williams N, Hill T. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus. J Gen Virol. 1993;74:1357–1362.
   Google Scholar
• Cantin EM, Hinton DR, Chen J, Openshaw H. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol. 1995;69:4898–4905.
   PubMed Web of Science ®Google Scholar
• Shimeld C, Whiteland JL, Nicholls SM, Grinfeld E, Easty DL, Hong G, Hill TJ. Immune cell infiltration and persis-tence in the mouse trigeminal ganglion after infection of the cornea with herpes simplex virus type 1. J Neuroim-munol. 1995;61: 7–16.
   Google Scholar
• Halford WP, Gebhardt BM, Can DJ. Persistent cytokine expression in trigeminal ganglion latently infected with herpes simplex virus type 1. J Immunol. 1996;157: 3542–3549.
   Google Scholar
• Liu T, Tang Q, Hendricks RL. Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. J Virol. 1996;70: 264–271.
   Google Scholar
• Chen SH, Garber DA, Schaffer PA, Knipe DM, Coen DM. Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation. Virology. 2000;278:207–216.
   Google Scholar
• Shimeld C, Whiteland JL, Williams NA, Easty DL, Hill TJ. Reactivation of herpes simplex virus type 1 in the mouse trigeminal ganglion: An in vivo study of virus antigen and immune cell infiltration. J Gen Virol. 1996;77: 2583–2590.
   Google Scholar
• Noisakran S, Carr DJ. Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia. J Neuroimmunol. 1999;95:126–135.
   PubMed Web of Science ®Google Scholar
• Jones CA, Taylor TJ, Knipe DM. Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model. Virology. 2000;278: 137–150.
   Google Scholar
• Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Nall Acad Sci USA. 1989;86:4736–4740.
   PubMed Web of Science ®Google Scholar
• Gao M, Knipe DM. Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J Virol. 1989;63:5258–5267.
   PubMedGoogle Scholar
• Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol. 2000;74: 7963–7971.
   Google Scholar
• Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection. J Virol. 1994;68:689–696.
   PubMed Web of Science ®Google Scholar
• Kramer NW, Coen DM. Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol. 1995;69:1389–1399.
   Google Scholar
• Katz JP, Bodin ET, Coen DM. Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J Virol. 1990;64:4288–4295.
   Google Scholar
• Pelosi E, Mulamba GB, Coen DM. Penciclovir and patho-genesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res. 1998;37:17–28.
   Google Scholar
• Swan MA. Improved preservation of ultrastructural mor-phology in human spermatozoa using betaine in the primary fixative. Int J And. 1997;20:45–54.
   Google Scholar
• Prophet EB, Mills B, Arrington JB, Sobin LH. Armed Forces Institute of Pathology Laboratory Methods in His-totechnology, Washington DC: American Registry of Pathology, 1994.
   Google Scholar
• Nuovo GJ. PCR in situ Hybridization: Protocols and Appli-cations. Philadelphia, PA: Lippincott-Raven Publishers, 1996.
   Google Scholar
• Tourtellotte WW, Verity AN, Schmid P, Martinez S, Shapshank P. Covvalent binding of formalin-fixed paraffin-embedded brain tissue sections to glass slides suitable for in situ hybridization. J Virol Methods. 1987;15: 87–99.
   Google Scholar
• Buechi M, Bachi T. Immunofluorescence and electron microscopy of the cytoplasmic surface of the human erythrocyte membrane and its interaction with Sendai virus. J Cell Biology. 1979;83:338–347.
   Google Scholar
• Leib DA, Coen DM, Bogard CL, Hicks KA, Yager DR, Knipe DM, Tyler KL, Schaffer PA. Immediate-early regu-latory gene mutants define different stages in the establish-ment and reactivation of herpes simplex virus latency. J Virol. 1989;63:759–768.
   PubMed Web of Science ®Google Scholar
• Jacobson JG, Ruffner KL, Kosz-Vnenchak M, Hwang CB, Wobbe KK, Knipe DM, Coen DM. Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia. J Virol. 1993;67:6903–6908.
   Google Scholar
• Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL. Macrophage control of herpes simplex virus type 1 repli-cation in the peripheral nervous system. J Immunol. 1999;162: 2895–2905.
   Google Scholar
• Valyi-Nagy T, Gesser RM, Raengsakulrach B et al. A thymidine kinase-negative HSV-1 strain establishes a per-sistent infection in SCID mice that features uncontrolled peripheral replication but only marginal nervous system involvement. Virology. 1994;199:484–490.
   PubMed Web of Science ®Google Scholar
• Gesser RM, Valyi-Nagy T, Fraser NW, Altschuler SM. Oral inoculation of SCID mice with an attenuated herpes simplex virus-1 strain causes persistent enteric nervous system infection and gastric ulcers without direct mucosal infection. Lab Invest. 1995;73:880–889.
   Google Scholar
• Gesser RM, Valyi-Nagy T, Fraser NW. Restricted herpes simplex virus type 1 gene expression within sensory neurons in the absence of functional B and T lymphocytes. Virology. 1994;200:791–795.
   PubMed Web of Science ®Google Scholar
• Ellison AR, Yang L, Voytek C, Margolis TP. Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains. Virology. 2000;268:17–28.
   Google Scholar
• Shimeld C, Hill TJ, Blyth WA, Easty DL. Passive immu-nization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. J Gen Virol. 1990;71:681–687.
   PubMed Web of Science ®Google Scholar
• Birmanns B, Reibstein I, Steiner I. Characterization of an in vivo reactivation model of herpes simplex virus from mice trigeminal ganglia. J Gen Virol. 1993;74:2487–2491.
   Google Scholar
• Manservigi R, Grossi MP, Gualandri R et al. Protection from herpes simplex virus type 1 lethal and latent infec-tions by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector. J Virol. 1990;64:431–436.
   Google Scholar
• Blacklaws BA, Nash AA. Immunological memory to herpes simplex virus type 1 glycoproteins B and D in mice. J Gen Virol. 1990;71:863–871.
   PubMedGoogle Scholar
• Heiligenhaus A, Wells PA, Foster CS. Immunisation against HSV-1 keratitis with a synthetic gD peptide. Eye. 1995; 9:89–95.
   Google Scholar
• Rajcani J, Sabo A, Mucha V, Kostal M, Compel P. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation. Acta Virol. 1995; 39:37–49.
   Google Scholar
• Kino Y, Eto T, Nishiyama K, Ohtomo N, Mori R. Immuno-genicity of purified glycoprotein gB of herpes simplex virus. Arch Virol. 1986;89:69–80.
   Google Scholar
• Kramer MF, Chen SH, Knipe DM, Coen DM. Accumula-tion of viral transcripts and DNA during establishment of latency by herpes simplex virus. J Virol. 1998;72:1177–1185.
   Google Scholar
• Linnavuori K, Hovi T. Restricted replication of herpes simplex virus in human monocyte cultures: Role of inter-feron. Virology. 1983;130:1–9.
   Google Scholar
• Yamada M, Arao Y, Hatano A, Uno F, Nii S. Effect of recombinant mouse interferon-beta on acute and latent herpes simplex infection in mice. Arch Virol. 1988;99:101–109.
   Google Scholar
• Feduchi E, Alonso MA, Carrasco L. Human gamma inter-feron and tumor necrosis factor exert a synergistic block-ade on the replication of herpes simplex virus. J Virol. 1989;63:1354–1359.
   Google Scholar
• Hendricks RL, Weber PC, Taylor JL, Koumbis A, Tumpey TM, Glorioso JC. Endogenously produced interferon alpha protects mice from herpes simplex virus type 1 corneal disease. J Gen Virol. 199172:1601-1610.
   PubMed Web of Science ®Google Scholar
• Halford WP, Veress LA, Gebhardt BM, Carr DJ. Irmate and acquired immunity to herpes simplex virus type 1. Virology. 1997;236:328–337.
   Google Scholar
• Berkowitz C, Becker Y. Recombinant interleukin-1 alpha, interleukin-2 and M-CSF-1 enhance the survival of newborn C57BL/6 mice inoculated intraperitoneally with a lethal dose of herpes simplex virus-1. Arch Virol. 1992;124:83–93.
   Google Scholar
• Bouley DM, Kanangat S, Wire W, Rouse BT. Characteri-zation of herpes simplex virus type-1 infection and herpetic stromal keratitis development in IFN-gamma knockout mice. J Immunol. 1995;155:3964–3971.
   PubMed Web of Science ®Google Scholar
• Martin S, Zhu )0C, Silverstein SJ, Courtney RJ, Yao F, Jenkins FJ, Rouse BT. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0. J Gen Virol. 1990;71: 2391–2399.
   Google Scholar
• Banks TA, Nair S, Rouse BT. Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epi-topes of the immediate-early protein ICP27 of herpes simplex virus. J Virol. 1993;67: 613–616.
   Google Scholar
• Banks TA, Jenkins FJ, Kanangat S et al. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge. Virology. 1994;200:236–245.
   Google Scholar
• Manickan E, Francotte M, Kuklin N, Dewerchin M, Molitor C, Gheysen D, Slaoui M, Rouse BT. Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Thl+ T cells. J Virol. 1995;69:4711–4716.
   PubMed Web of Science ®Google Scholar
• Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med. 2000;191: 1459–1466.
   Google Scholar